- Complete therapeutic response to anti-PD1 therapy in patient with advanced melanoma and resistance to targeted therapy of BRAF inhibitors2018 | First Faculty of Medicine
- Advances in the treatment of metastatic melanoma2018 | First Faculty of Medicine
- Trametinib2016 | First Faculty of Medicine
- Severe diclofenac photoallergy in a patient treated with vemurafenib2016 | Third Faculty of Medicine
- Patient with abrain metastases of malignant melanoma a long-term surviving with BRAF and MEK inhibitor in combination therapy2018 | First Faculty of Medicine
- Dabrafenib in the treatment of metastatic melanoma2014 | Publication without faculty affiliation
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study2016 | Faculty of Medicine in Hradec Králové
- Dual targeted therapy in patients with malignant melanoma2017 | Faculty of Medicine in Hradec Králové
- Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report2020 | Faculty of Pharmacy in Hradec Králové
- BRAF/MED inhibitors in the treatment of malignant melanoma2018 | Third Faculty of Medicine
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma2020 | First Faculty of Medicine
- Skin toxicity of BRAF and MEK inhibitors2021 | First Faculty of Medicine
- Effect of target therapy with BRAF and MEK inhibitors on the immune system in metastatic melanoma2023 | First Faculty of Medicine
- Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/Management2014 | Faculty of Medicine in Hradec Králové
- Targeted therapy in metastatic melanoma2014 | Publication without faculty affiliation
- Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma2016 | Second Faculty of Medicine
- Gastrointestinal stromal tumour: advances in treatment2020 | Publication without faculty affiliation
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine
- Nonhealing atopic eczema2017 | Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Alopecia and hair damage induced by oncological therapy2019 | Faculty of Medicine in Pilsen
- Quantitative changes of melanoma-associated antigens as a biomarker for targeted therapy response2016 | Third Faculty of Medicine
- Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy2022 | Faculty of Pharmacy in Hradec Králové
- Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo2022 | Faculty of Medicine in Hradec Králové, Faculty of Pharmacy in Hradec Králové
- Advances in the treatment of metastatic melanoma2013 | Publication without faculty affiliation
- Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach2022 | Publication without faculty affiliation
- Progress in the treatment of cerebral metastases in advanced melanoma2018 | Publication without faculty affiliation
- An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system2019 | First Faculty of Medicine
- Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition2020 | Second Faculty of Medicine
- Prognostic value of blood cell count-derived ratios in BRAF-mutated metastatic melanoma2022 | Faculty of Medicine in Hradec Králové
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publication without faculty affiliation
